Study The Effect Of Serotonin And Cholecystokinin In Men With Irritable Bowel Syndrome

Abstract

Irritable Bowel Syndrome (IBS) is a complex gastrointestinal disorder with an unclear etiology. Recent research highlights the gut-brain axis, particularly the roles of serotonin and cholecystokinin (CCK), as key factors in IBS pathophysiology. Altered serotonin signaling and CCK levels may contribute to IBS symptoms by influencing gastrointestinal motility and visceral sensitivity. A deeper understanding of these relationships could lead to improved diagnostic tools and more effective treatment strategies for IBS patients.
IBS is more frequently studied in women, while its presentation in men remains underexplored. This study investigated IBS-related biomarker levels in 90 adult male patients diagnosed at Falluja General Hospital between October 2023 and July 2024. Serum levels of serotonin, cholecystokinin, and selenium were measured and compared with those of 40 healthy controls. Statistical analysis used IBM SPSS v27.0, with independent samples t-tests (p < 0.05).
The results revealed significant alterations in CCK, serotonin, and selenium levels between IBS patients and controls, suggesting their potential role in IBS pathophysiology. Strong correlations among these biomarkers indicate a complex interplay of physiological processes. Notably, all three parameters demonstrated high diagnostic performance, with CCK and serotonin exhibiting near-perfect discrimination. These findings highlight their potential as valuable biomarkers for IBS diagnosis and screening. However, the exceptionally high diagnostic accuracy, particularly of CCK, necessitates further validation in larger, more diverse populations. The slightly superior diagnostic performance of CCK and serotonin compared to selenium suggests their prioritization in clinical applications. These findings support their potential as IBS biomarkers, warranting further research to confirm their clinical utility.